AIR® inhaled insulin system: A novel insulin-delivery system for patients with diabetes

Expert Review of Medical Devices

Volumn 4, Issue 5, 2007, Pages 683-692

  Rosenstock, Julio ^a   Muchmore, Douglas ^b   Swanson, Diana ^c   Schmitke, Jennifer ^d  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c i3Statprobe ^*  (United States)

^d ALKERMES INC   (United States)

Author keywords

Aerosols; Diabetes mellitus; Drug delivery systems; Hyperglycemia; Inhaled insulin; Insulin; Powders

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETIC PATIENT; DRUG ABSORPTION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRY POWDER; EXHALATION; FORCED EXPIRATORY VOLUME; GLYCEMIC CONTROL; HEALTH INSURANCE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INHALATION; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LIPOHYPERTROPHY; METERED DOSE INHALER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARTICLE SIZE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RESPIRATORY AIRFLOW; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WEIGHT GAIN; COST BENEFIT ANALYSIS; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; REVIEW;

ADMINISTRATION, INHALATION; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN;

EID: 34848878587     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.4.5.683     Document Type: Article

References (47)

1. American Diabetes Association. Standards of medical care in diabetes - 2007. Diabetes Care 30(Suppl. 1), S4-S41 (2007).
2. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29(8), 1963-1972 (2006).
3. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 28(1), 78-83 (2005).
4. Saaddine JB, Cadwell B, Gregg EW et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988-2002. Ann. Intern. Med. 144(7), 465-474 (2006).
5. Brown JB, Nichols GA, Perry A. The burden of treatment failure in Type 2 diabetes. Diabetes Care 27(7), 1535-1540 (2004).
6. Korytkowski M. When oral agents fail; practical barriers to starting insulin. Int. J. Obes. Relat. Metab. Disord. 26(Suppl. 3), S18-S24 (2002).
7. Peyrot M, Rubin RR, Lauritzen T et al. Resistance to insulin therapy among patients and providers: results of the crossnational Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 28(11), 2673-2679 (2005).
8. Hayes RP, Bowman L, Monahan PO, Marrero DG, McHorney CA. Understanding diabetes medications from the perspective of patients with Type 2 diabetes: prerequisite to medication concordance. Diabetes Educ. 32(3), 404-414 (2006).
9. Heinemann L. Alternative delivery routes: inhaled insulin. Diabetes Nutr. Metab. 15(6), 417-422 (2002).
10. Patton JS. Unlocking the opportunity of tight glycaemic control. Innovative delivery of insulin via the lung. Diabetes Obes. Metab. 7(Suppl. 1), S5-S8 (2005).
11. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci. 75(5). 433-438 (1986).
12. Barnett AH. Exubera inhaled insulin: a review. Int. J Clin. Pract. 58(4), 394-401 (2004).
13. Fineberg SE. Diabetes therapy trials with inhaled insulin. Expect Opin. Investig. Drugs 15(7), 743-762 (2006).
14. Mandal TK. Inhaled insulin for diabetes mellitus. Am. J. Health Syst. Pharm. 62(13), 1359-1364 (2005).
15. Muchmore DB, Gates JR. Inhaled insulin delivery - where are we now? Diabetes Obes. Metab. 8(6), 634-642 (2006).
16. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv. Drug Deliv. Rev. 58(9-10), 1061-1075 (2006).
17. Exubera® Medication Guide, Pfizer Inc., NY, USA: Nektar Therapeutics, CA, USA (2006).
18. Exubera® US Package Insert, Pfizer Inc., NY, USA; Nektar Therapeutics, CA, USA (2006).
19. Skyler JS, Jovanovic L, Klioze S et al. Two-year safety and efficacy of inhaled human Insulin (Exubera) in adult patients with Type 1 diabetes. Diabetes Care. 30, 579-585 (2007).
20. Brunner GA, Balent B, Ellmerer M et al. Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia 44(3), 305-308 (2001).
21. Thipphawong J, Otulana B, Clauson P, Okikawa J, Farr SJ. Pulmonary insulin administration using the AERx insulin diabetes system. Diabetes Technol. Ther. 4(4), 499-504 (2002).
22. Rave KM, Nosek L, de la Pena A et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro, Diabetes Care 28(10), 2400-2405 (2005).
23. Henry R, Sunder M, Fryburg D et al. Within-subject variability of inhaled insulin (Exubera® ) versus subcutanous regular insulin in elderly obese patients with Type 2 diabetes mellitus. Diabetes52 (Suppl. 1), A105 (2003).
24. Gelfand RA, Schwartz SL, Horton M. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with Type 2 diabetes mellitus. Diabetes 47(Suppl. 1), 99 (1998).
25. Pfutzner A, Manh AE, Steiner SS. Technosphere/Insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol. Ther. 4(5), 589-594 (2002).
26. Richardson PC, Boss AH. Technosphere insulin technology. Diabetes Technol. Ther. 9(Suppl. 1), S65-S72 (2007).
27. Rave K, Heise T, Pfutzner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled Technosphere® insulin in comparison to subcutaneously injected regular human insulin in subjects with Type 2 diabetes. Diabetes Care (2007) (Epub ahead of print).
28. Tu N, Kramer D, Baughman R. Inhaled Technosphere®/Insulin improves glycemic control without weight gain. Diabetes 56(Suppl. 1), 571 (2007).
29. Hausmann M, Dellweg S, Osborn C et al. Inhaled insulin as adjunctive therapy in subjects with Type 2 diabetes failing oral agents: a controlled proof-of-concept study. Diabetes Obes. Metab. 8(5), 574-580 (2006).
30. Rosenstock J, Foyt H, Klioze S et al. Inhaled human insulin (Exubera) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with Type 2 diabetes (T2DM). Diabetes 55(Suppl. 1), A26 (2006).
31. Wise RA, Ahrens R, Jensen RL et al. Standardized measurement of single breath diffusing capacity (DLco) in a multicenter clinical trial. Proc. Am. Thorac. Soc. 3, A22 (2006).
32. Harris R, Blonshine S, Baughman R. Ensuring reliable pulmonary safety assessment for the development of Technosphere®/Insulin (T/I). Diabetes 56(Suppl. 1), 35 (2007).
33. Jensen RL, Crapo RO, Sun B, Muchmore DB. Implementation of central quality assurance (QA) for PFTs in a multi-center inhaled insulin trial. Proc. Am. Thorac. Soc. 3, A66 (2006).
34. Garg S, Rosenstock J, Silverman BL et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with Type 1 diabetes. Diabetologia 49(5), 891-899 (2006).
35. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab. 90(6), 3287-3294 (2005).
36. Finco-Kent D, Krasner A, Williams D, Duggan W, Kawabata T. lgG subclass analysis of insulin antibodies in patients with Type 1 diabetes treated with inhaled human insulin (Exubera®) and subcutaneous insulin. Diabet. Med. 23(Suppl. 4), P897 (2006).
37. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J. Appl. Physiol. 85(2), 379-385 (1998).
38. Edwards DA, Hanes J, Caponetti G et al. Large porous particles for pulmonary drug delivery. Science 276(5320), 1868-1871 (1997).
39. DeLong M, Wright J, Dawson M, Meyer T, Sommerer K, Dunbar C. Dose delivery characteristics of the AIR pulmonary delivery system over a range of inspiratory flow rates. J. Aerosol Med. 18(4), 452-459 (2005).
40. Rawlins M. Inhaled insulin. Lancet 368(9529), 26-27 (2006).
41. Freemantle N, Strack TR. Will availability of inhaled human insulin (Exubera®) improve management of Type 2 diabetes? The design of the Real World trial. Trials 7, 25 (2006).
42. Gern JE, Stone CK, Nakano M et al. Effect of upper respiratory tract infection on air inhaled insulin pharmacokinetics and glucodynamics in healthy subjects. Clin. Pharmacol. Ther. (2007) (Epub ahead of print).
43. Rave K, de la Peña A, Tibaldi F et al. AIR Inhaled Insulin in subjects with chronic obstructive pulmonary disease. Diabetes Care 30(7), 1777-1782 (2007).
44. Cefalu WT, Rosenstock J, Bindra S. Inhaled insulin: a novel route for insulin delivery. Expert Opin. Investig. Drugs 11 (5), 687-691 (2002).
45. Rosenstock J, Nakano M, Silverman BL et al. Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with Type 2 diabetes: efficacy, safety, and training measures. Diabetes Technol. Ther. 9(1), 80-88 (2007).
46. Hayes RP, Nakano M, Muchmore D. Schmitke J. Effect of standard (self-directed) training versus intensive training for Lilly/Atkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the system. Diabetes Technol. Ther. 9(1), 89-98 (2007).
47. Hayes RP, Muchmore D, Schmitke J. Effect of inhaled insulin on patient-reported outcomes and treatment preference in patients with Type 1 diabetes. Curr. Med. Res. Opin. 23(2), 435-442 (2007).